BIOMAT Database Logo BIOMAT Database Logo

Systemic treatment of Darier's disease with an oral retinoic acid derivative Ro 10-9359 Tigason. 1981

D E Greig, and J Wishart, and J L Hodge

In an open trial, seven patients with Darier's disease took part in a three month study to evaluate the effect of a new oral synthetic retinoid. Ro 10-9359 (Tigason). The usual dose was 50 mg daily. At two-week intervals, lesions were graded with respect to their nature, erythema, keratosis, and percent of body surface area involved. All but one patient, were markedly improved on the drug, and showed a marked preference for the retinoid above other treatments. No patients withdrew because of side-effects but all suffered dry lips. Other side-effects were mild or moderate and well tolerated. It is concluded that Tigason is effective in Darier's disease.

UI MeSH Term Description Entries
D007644 Darier Disease An autosomal dominantly inherited skin disorder characterized by warty malodorous papules that coalesce into plaques. It is caused by mutations in the ATP2A2 gene encoding SERCA2 protein, one of the SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES. The condition is similar, clinically and histologically, to BENIGN FAMILIAL PEMPHIGUS, another autosomal dominant skin disorder. Both diseases have defective calcium pumps (CALCIUM-TRANSPORTING ATPASES) and unstable desmosomal adhesion junctions (DESMOSOMES) between KERATINOCYTES. Acrokeratosis Verruciformis of Hopf,Darier-White Disease,Keratosis Follicularis,Acantholytic Dyskeratotic Epidermal Nevi,Acantholytic Dyskeratotic Epidermal Nevus,Acrokeratosis Verruciformis,Darier's Disease,Hopf Disease,Darier White Disease,Darier-White Diseases,Dariers Disease,Disease, Darier,Disease, Darier's,Disease, Darier-White,Disease, Hopf,Diseases, Darier-White,Diseases, Hopf,Hopf Acrokeratosis Verruciformis,Hopf Diseases,Verruciformis, Acrokeratosis
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005050 Etretinate An oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. Beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. The compound may be teratogenic. B10-9359,Ethyl Etrinoate,Ro 10-9359,Ro-10-9359,Tigason,Tigazon,B10 9359,B109359,Etrinoate, Ethyl,Ro 10 9359,Ro 109359,Ro109359
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014212 Tretinoin An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). Retinoic Acid,Vitamin A Acid,Retin-A,Tretinoin Potassium Salt,Tretinoin Sodium Salt,Tretinoin Zinc Salt,Vesanoid,all-trans-Retinoic Acid,beta-all-trans-Retinoic Acid,trans-Retinoic Acid,Acid, Retinoic,Acid, Vitamin A,Acid, all-trans-Retinoic,Acid, beta-all-trans-Retinoic,Acid, trans-Retinoic,Potassium Salt, Tretinoin,Retin A,Salt, Tretinoin Potassium,Salt, Tretinoin Sodium,Salt, Tretinoin Zinc,Sodium Salt, Tretinoin,Zinc Salt, Tretinoin,all trans Retinoic Acid,beta all trans Retinoic Acid,trans Retinoic Acid

Related Publications

D E Greig, and J Wishart, and J L Hodge
Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro 10-9359).
February 1980, The British journal of dermatology,
D E Greig, and J Wishart, and J L Hodge
Treatment of dyskeratosis follicularis Darier with the retinoic acid derivative Ro 10-9359 (Tigason).
January 1981, Dermatologica,
D E Greig, and J Wishart, and J L Hodge
Systemic treatment of Darier's disease with a new retinoid (RO 10-9359).
May 1979, Archives of dermatological research,
D E Greig, and J Wishart, and J L Hodge
[Oral treatment of various dermatosis with the aromatic derivative of retinoic acid Ro 10-9359].
January 1978, Medicina cutanea ibero-latino-americana,
D E Greig, and J Wishart, and J L Hodge
Monilethrix treated with the oral retinoid Ro 10-9359 (Tigason).
July 1983, Clinical and experimental dermatology,
D E Greig, and J Wishart, and J L Hodge
Treatment of psoriasis vulgaris with a new retinoic acid derivative Ro 10-9359; An uncontrolled clinical trial.
January 1977, Dermatologica,
D E Greig, and J Wishart, and J L Hodge
Effects of etretinate (Ro 10-9359) on Darier's Disease.
August 1982, Dermatologica,
D E Greig, and J Wishart, and J L Hodge
Treatment of psoriasis by oral PUVA therapy combined with aromatic retinoid (Ro 10-9359; Tigason).
January 1981, Dermatologica,
D E Greig, and J Wishart, and J L Hodge
Tigason (Ro 10-9359) treatment in an alcoholic patient with psoriasis of verrucous type.
August 1982, Dermatologica,
D E Greig, and J Wishart, and J L Hodge
[Systemic treatment of oral lichen planus with an aromatic retinoid (Ro 10-9359)].
October 1979, Zeitschrift fur Hautkrankheiten,
Copied contents to your clipboard!